Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Mark Ragosa Sells 36,783 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 36,783 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $92.16, for a total value of $3,389,921.28. Following the completion of the transaction, the chief financial officer owned 20,854 shares in the company, valued at $1,921,904.64. The trade was a 63.82% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Up 2.7%

KNSA traded up $2.49 on Tuesday, hitting $93.29. 1,021,631 shares of the company’s stock were exchanged, compared to its average volume of 705,858. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $37.02 and a fifty-two week high of $98.48. The firm has a 50-day moving average price of $79.39 and a 200-day moving average price of $60.29. The stock has a market cap of $7.28 billion, a price-to-earnings ratio of 71.76 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The business had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. On average, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.26 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on KNSA shares. The Goldman Sachs Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. JPMorgan Chase & Co. boosted their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a report on Friday. Canaccord Genuity Group upped their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Finally, Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and a consensus price target of $100.57.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Allworth Financial LP lifted its stake in shares of Kiniksa Pharmaceuticals International by 42.0% in the 2nd quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after purchasing an additional 134 shares during the last quarter. Arizona State Retirement System increased its position in shares of Kiniksa Pharmaceuticals International by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after purchasing an additional 209 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Kiniksa Pharmaceuticals International by 21.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock worth $95,000 after purchasing an additional 223 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Kiniksa Pharmaceuticals International by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock worth $811,000 after purchasing an additional 237 shares during the last quarter. Finally, First Trust Advisors LP raised its holdings in Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after buying an additional 293 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.